Study of thyroid dysfunction in metabolic syndrome and association with its components

Saluja, Manoj; Pyarsabadi, Pavankumar; Jelia, Shivcharan; Chittora, Saurabh; Swami, Yogesh Kumar; Vimlani, Hemant

doi:10.1016/j.cmrp.2017.11.010

Cited by 9 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likely this is due to different clinical characteristics of the various study populations. For example, high prevalence numbers of subclinical hypothyroidism were reported in studies from India (21,39,40,41), where it is reported that a high prevalence of endemic goiter persists despite the implementation of iodized salt (42). Lastly, it should be noted that patients treated with levothyroxine were classified as having hypothyroidism.…”

Section: Discussionmentioning

confidence: 99%

“…Four studies determined obesity by WC, the other studies by BMI. Two studies did not specify a definition of (subclinical) hypothyroidism (15,21) and four studies (14,17,18,22) classified patients on thyroxine substitution as hypothyroid. All other studies diagnosed (subclinical) hypothyroidism based on raised TSH levels; two studies measured TSH levels after administration of thyrotropinreleasing hormone (TRH) intravenously (23,24).…”

Section: Risk Of Biasmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis

Hulsteijn

Pasquali

Casanueva

et al. 2020

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective The increasing prevalence of obesity is expected to promote the demand for endocrine testing. To facilitate evidence guided testing, we aimed to assess the prevalence of endocrine disorders in patients with obesity. The review was carried out as part of the Endocrine Work-up for the Obesity Guideline of the European Society of Endocrinology. Design Systematic review and meta-analysis of the literature. Methods A search was performed in MEDLINE, EMBASE, Web of Science and COCHRANE Library for original articles assessing the prevalence of hypothyroidism, hypercortisolism, hypogonadism (males) or hyperandrogenism (females) in patients with obesity. Data were pooled in a random-effects logistic regression model and reported with 95% confidence intervals (95% CI). Results Sixty-eight studies were included, concerning a total of 19.996 patients with obesity. The pooled prevalence of overt (newly diagnosed or already treated) and subclinical hypothyroidism was 14.0% (95% CI: 9.7–18.9) and 14.6% (95% CI: 9.2–20.9), respectively. Pooled prevalence of hypercortisolism was 0.9% (95% CI: 0.3–1.6). Pooled prevalence of hypogonadism when measuring total testosterone or free testosterone was 42.8% (95% CI: 37.6–48.0) and 32.7% (95% CI: 23.1–43.0), respectively. Heterogeneity was high for all analyses. Conclusions The prevalence of endocrine disorders in patients with obesity is considerable, although the underlying mechanisms are complex. Given the cross-sectional design of the studies included, no formal distinction between endocrine causes and consequences of obesity could be made.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Risk Of Biasmentioning

confidence: 99%

Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis

Hulsteijn

Pasquali

Casanueva

et al. 2020

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Thyroid gland dysfunction contributes to components of MS, including weight gain, lipid disorders, and HT. Among studies that have investigated the relationship between thyroid dysfunction and MS, 23 - 25 ) most assessed thyroid function in MS 26 , 27 ) or MS in euthyroid populations or in those with subclinical hypothyroidism. 28 , 29 ) These studies showed that the presence of MS was associated with a significantly increased risk of developing subclinical hypothyroidism and that individuals with higher TSH levels had an increased risk of MS.…”

Section: Discussionmentioning

confidence: 99%

Predictability of Metabolic Syndrome Diagnosed by Body Mass Index for Cardiovascular Risk in Older Patients Treated with Levothyroxine

Koçak¹,

Savaş

Saraç

2022

Ann Geriatr Med Res

View full text Add to dashboard Cite

Background: We investigated the prevalence and metabolic features of two definitions of metabolic syndrome (MS) between older patients with chronic thyroiditis treated with levothyroxine (LT4) and controls. We also assessed the ability of both criteria to predict cardiovascular (CV) risk.Methods: This cross-sectional, retrospective study included individuals aged ≥60 years who attended a geriatric outpatient clinic between January 2015 and December 2018. The LT4 treatment group was classified as having high or low CV risk based on the Framingham score.Results: This study enrolled 111 patients with chronic thyroiditis treated with LT4 and 131 patients without thyroid disease as the control group. The prevalence of MS according to the World Health Organization (WHO) criteria and American Association of Clinical (AACE) criteria was similar in the LT4 treatment (21.6% and 26.1%, respectively) and the control (30.5% and 34.4%, respectively) groups (p>0.05). While the prevalence of MS and CV risk did not differ significantly between the control and LT4 treatment groups, the prevalence of MS with both definitions was higher among individuals with high CV risk in the LT4 treatment group (p<0.05). For the prediction of CV risk, the sensitivity and specificity of the AACE criteria were higher than those of the WHO criteria in the LT4 treatment group. Conclusions: The prevalence of MS in euthyroid patients treated with LT4 was similar to that of patients without thyroid disease. When the LT4 treatment group was classified based on CV risk, MS was more common in those with a high CV risk.

show abstract

“…3 In addition the incidence of hypothyroidism increases with age and is more common in women. 4 The prevalence of T2DM (about 90%) is greater compared to that of T1DM (about 10%) among the diabetes mellitus population due to increase in sedentary lifestyle and obesity. Also, the incidence of hypothyroidism is higher in T2DM patients than in T1DM patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical Evidence of Association Between Type-2 Diabetes Mellitus and Hypothyroidism with Therapeutic Relevance—An Observational Study

Gurunath¹,

Koyyada²,

Krishna³

et al. 2019

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

Background: Thyroid disorder and diabetes are associated endocrine disorders. Patients with either one of the disorders are at great risk of developing the other. The coexistence of type-2 diabetes mellitus (T2DM) and hypothyroidism with clinical evidence of effect on one another has not been reported until today. Methods: This prospective study involved 702 patients. Each participant's blood sugar levels and thyroid profiles were statistically analyzed using unpaired t-test. Results: The incidence of hypothyroidism and hyperthyroidism in diabetic patients was 20.2% and 1.71% respectively, while the incidence of type-1 diabetes mellitus and T2DM in thyroid dysfunction patients was 0.56% and 19.03% respectively. The mean fasting blood sugars and postprandial blood sugar levels, triiodothyronine, thyroxine and Thyroid stimulating hormone levels of hypothyroid patients with T2DM (

show abstract

Study of thyroid dysfunction in metabolic syndrome and association with its components

Cited by 9 publications

References 11 publications

Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis

Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis

Predictability of Metabolic Syndrome Diagnosed by Body Mass Index for Cardiovascular Risk in Older Patients Treated with Levothyroxine

Clinical Evidence of Association Between Type-2 Diabetes Mellitus and Hypothyroidism with Therapeutic Relevance—An Observational Study

Contact Info

Product

Resources

About